Medable Expands Adoption of Agentic AI in Clinical Development with Alveus Therapeutics

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of agentic AI in drug development, today announced it is bringing agentic AI to Alveus Therapeutics, a clinical-stage biotech developing next-generation medicines for obesity and metabolic disease. The Clinical Oversight Agent is intended to support the review of clinical development information by the Alveus clinical team.

Through Medable’s Agentic Accelerator Program, Medable’s Forward Deployed Engineers (FDEs) work alongside sponsor teams to configure AI agents around their specific studies and workflows. Alveus is working with the FDE team to configure the Clinical Oversight Agent for its clinical oversight needs.

Built on Medable Agent Studio, the Clinical Oversight AI Agent provides sponsors with trial intelligence across the e-clinical enterprise landscape. It connects to EDC, IRT, CTMS, and other relevant systems to identify and prioritize emerging trial- and site-level signals and recommend actions related to participant enrollment and retention, data quality, protocol adherence, monitoring performance, and delivery, with the supporting evidence behind each recommendation available for clinical teams to review. Alveus joins major global pharmaceutical companies using the Medable Agent Studio.

“Medable agentic AI delivers a critical competitive edge for our customers so that they can win the development race in big markets,” said Michelle Longmire, Medable Chief Executive Officer. “Our goal is to bring biotechs an entirely differentiated level of insight and clarity into the operations of their trials with the aim of reducing the timelines compared to standard development efforts.”

Learn more how Medable agents are improving clinical trials at HLTH USA in Las Vegas (Nov 15-18, 2026) at Medable booth #4012.

About Alveus Therapeutics

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation medicines for obesity and metabolic disease, focused on durability, tolerability, body composition, and simplicity. Alveus works across the United States and Europe and collaborates with scientific and development partners globally. The company's mission is to make weight loss last. For more information, visit alveustx.com.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation and ranking on the TIME “World’s Top Healthtech Company” list, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Learn more at medable.com.